CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--NuPathe Inc., a privately held specialty pharmaceutical company, today announced positive results from an initial Phase I study of NP101 SmartRelief™, a novel treatment for acute migraine being developed by NuPathe.
NP101 combines NuPathe’s SmartRelief™ proprietary iontophoretic transdermal technology with sumatriptan, the most widely prescribed treatment for acute migraine in the United States. Sumatriptan is also the active ingredient in IMITREX®, which is also indicated for the treatment of acute migraine.
